Intercell and Novartis collaborate on Pseudomonas vax

Intercell and Novartis are continuing to test an investigational vaccine for Pseudomonas aeruginosa. The disease can cause nosocomial infections that lead to pneumonia and other infections, usually during hospital stays, particularly in patients on ventilators. The 400-patient efficacy trial should start in the first half of 2012. Intercell release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.